Goleta medical device maker stocks are hot
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen partnering to develop new drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Balancing act: Camarillo company helps elderly with movement
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Conejo Valley biotech scene heats up with Sienna IPO
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s Kyprolis found to increase cancer survival rate
A Phase 3 clinical study of Amgen’s multiple myeloma drug Kyprolis showed that it increased overall survival rate when paired with lenalidomide and dexamethasone versus just those two drugs alone. The drug reduced the risk of death by 21 percent, and patients lived 7.9 months longer when on a regimen that included Kyprolis than those Read More →
FDA gives full approval to Amgen leukemia drug Blincyto
Amgen’s leukemia drug Blincyto received full approval from the U.S. Food and Drug Administration on July 11 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children. The biotech giant, headquartered in Thousand Oaks, had previously announced that the drug had been fast-tracked for priority review. The full approval includes data Read More →
Sienna Biopharmaceuticals files for $75 million IPO
Westlake Village biotechnology company Sienna Biopharmaceuticals filed for an initial public offering with the Securities and Exchange Commission on June 3, stating expectations to raise up to $74.75 million. Founded in 2010, the company develops clinical-stage topical therapies for inflammatory skin diseases and other conditions. ARCH Venture Partners and Venvest Capital led a $40 million Read More →
